Abstract
Hepatocellular carcinoma (HCC) is a highly complex cancer, resistant to commonly used treatments and new therapeutic agents are urgently needed. A total of thirty-two thieno [3,2- and a cell cycle arrest in the G2/M phase. QSAR studies were also performed and the correlations obtained using molecular and 1D descriptors revealed the importance of the presence of amino groups and hydrogen bond donors for anti-HCC activity, and hydrogen bond acceptors for hepatotoxicity. The best correlations were obtained with
Introduction
Hepatocellular carcinoma (HCC) is a major health problem with more than 660,000 new cases per year worldwide [1] . HCC is a rapid fatal disease with a life expectancy of about 6
months from the time of diagnostics, and has the third highest mortality rate among all cancers [2] . The highest prevalence for HCC occurs in Asia and sub-Saharan Africa countries, mainly due to endemic hepatitis B and C and food contaminated by Aflatoxin B.
In Western countries and Japan, the incidence has increased dramatically over the past decades, mainly due to the rise in hepatitis C virus (HCV) infection, cirrhosis related to type II diabetes, and non-alcoholic steatohepatitis [3, 4] .
Despite the available surgical treatment options, the majority of HCC patients have inoperable disease with very poor prognosis [5, 6] . Also, the frequent presence of recurrence, metastasis or the development of new primary tumors, results in survival rates of 25-50% 5-year after surgery [7] . Alternative or palliative treatment options are very limited due to resistance to conventional chemotherapy and radiotherapy [8] . Because of the lack of survival benefits of treatment with conventional drugs, there is a need for more therapies with pharmacological agents, to help improve the prognosis of patients with HCC.
Sorafenib, a multikinase inhibitor, is the only approved drug for HCC treatment, although it is effective in a wide range of tumor models [9] . In vivo and in vitro studies have shown that sorafenib inhibits tumor growth and disrupts tumor microvasculature through antiproliferative, antiangiogenic, and/or pro-apoptotic effects. Sorafenib has shown antitumor activity in phase II/III trials involving patients with advanced renal cell carcinoma and hepatocellular carcinoma. The multiple molecular targets of sorafenib, the serine/threonine kinase Raf and VEGFR (the proangiogenic vascular endothelial growth factor receptor) and PDGFR (platelet-derived growth factor receptor) tyrosine kinases, may explain its broad preclinical and clinical activity [10] . The relative success of Sorafenib, which was found to prolong about 3 months the average survival time of patients with advanced HCC, suggests that the small-molecule targeted chemotherapy can be a promising strategy to combat this cancer [11] . In fact several compounds are already under preclinical investigation, and accumulating evidence suggests that combination therapy targeting different pathways will potentiate anti-cancer effects and will become the future therapeutic approach [8] .
The HepG2, Hep3B, Huh7.5 and SK-Hep1 are the commonly used human HCC cell lines [12] . Nevertheless, HepG2 is the most widely used cell line and generally regarded as a good HCC model [13] [14] [15] .
In this study, thirty two methyl 3-aminothieno[3,2-b]pyridine-2-carboxylate derivatives, synthesized in our group [16] [17] [18] , were evaluated as potential new anti-HCC agents by studying their in vitro cell growth inhibition activity using HepG2 cells. Furthermore, an initial assessment of possible compound hepatotoxicity was performed by studying their in vitro cell growth inhibition activity in a porcine liver primary cell culture (PLP1). The cell culture methodology to establish PLP1 as a good initial model for in vitro hepatotoxicity is described. The cell profile of the most promising compound (more active and less toxic) was analysed. QSAR (Quantitative Structure-Activity Relationships) studies were also performed for the anti-HCC activity and hepatotoxicity in order to provide some insights on the molecular interactions of the compounds studied with proteins involved in signaling pathways.
Results and Discussion

Establishment of a porcine liver primary cell culture for hepatotoxicity studies
In order to perform a preliminary study of in vitro toxicity in normal liver cells a porcine This assay is very important since mammalian hepatocytes still represent an obligatory step in the evaluation of toxic compounds that lead to the production of various metabolites, which are the ultimate cause of toxicity. We used porcine liver as an in vitro cytotoxicity model because it is known, in terms of cellular and physiological functioning, to be very similar to human [20] . The use of non-tumor liver cells is even more important in this work, as we are studying the effect of the methyl 3-aminothieno[3,2-b]pyridine-2-carboxylates derivatives in liver cancer (hepatocellular carcinoma). Although a human primary cell culture or even fresh isolated human hepatocytes would be preferred, there are still a number of ethical concerns to consider when using fresh human tissue for cell lines establishment. The use of porcine primary cells allows for a preliminary toxicity screening of the compounds in normal liver cells. This screening narrows the number of compounds that will then be further screened, using in vitro and/or in vivo human liver for hepatotoxicity.
Although the use of the PLP1 culture will not give us a definite answer on hepatotoxicity (none in vitro screening will do that), it is still a cheap, fast and ethically defensible way to perform preliminary hepatotoxicity studies.
Anti-hepatocellular carcinoma activity using human HepG2 cells and hepatotoxicity: SAR analysis
In this study, a total of thirty-two methyl 3-amino-thieno Results are given in concentrations that were able to cause 50% of cell growth inhibition (GI 50 ) after a continuous exposure of 72 h and show means ± SEM of three-independent experiments. Ellipticine was used as a control. Results are given in concentrations that were able to cause 50% of cell growth inhibition (GI 50 ) after a continuous exposure of 72 h and show means ± SEM of three-independent experiments. Ellipticine was used as a control.
To better rationalize the results, the five most potent compounds for anti-HCC activity are presented in Figure 1 : 1d and 1j from the methyl 3-amino-6-(hetero)arylthieno [3,2- b]pyridine-2-carboxylates series (Table 1) ; 2f, 2g and 2l from the methyl 3-amino-6- Table 2 ). shows that, although it was not possible to calculate GI 50 values for compounds 1d and 2g, due to low hepatotoxicity, they still presented a small percentage of PLP1 cell growth inhibition at the highest concentration evaluated of 125 µM. This is even more interesting when it was observed that the most potent anti-HCC compound 2f presents no hepatotoxicity, even at the highest concentrations evaluated.
In general we observe that, the presence of several substituents linked to position 6 of the methyl 3-aminothieno[3,2-b]pyridine-2-carboxylate moiety contributed to hepatotoxicity including: a dimethoxyphenyl in 1b and a methoxyphenylethynyl in 2d, a 6-fluoro-3-pyrid-3-yl in 1i and a pyrid-2-ylethynyl in 2m, a thien-3-yl in 1n and a thien-2-ylethynyl in 2l and notably quinolines (1p, 1q, 1r) . These compounds are not suitable scaffolds for pursuing synthesis of compounds with more efficient anti-HCC activity and low hepatotoxicity.
A recent study performed by Zeng et al. [13] showed a number of thieno [2,3- b]pyridine), this is an exciting evidence that corroborate the anti-HCC potential of the compounds presented in our study. However, the compounds presented in that study were not studied for hepatotoxicity and, based on the SAR analysis performed above, it is predicted that some of the compounds will probably present some degree of hepatotoxicity.
Taken together, our findings show that the most potent compounds presented in this work, above all 2f, are good candidates for chemotherapy against HCC, with minimal potential hepatotoxicity effects.
Therefore we further analyzed the cell cycle profile of exponentially growing HepG2 cells treated for 72h with compound 2f. The results are presented in Figure 3 . Since the cells were growing exponentially during the entire course of the experiment, the blank cells (treated with complete medium only) and control cells (treated with DMSO) presented a higher % of cells in S phase than that found in cells reaching confluence (data not shown).
Results from cells treated with compound 2f show that this compound causes a significant decrease in the % of cells in the S phase and a significant cell cycle arrest (increase in the % of cells) in the G2/M phase of the cell cycle. The cell cycle analysis allowed us to verify that following treatment of cells with compound 2f, there was only a slight (not statistically significant) increase in the sub-G1 peak (which is suggestive of apoptosis) indicating that the mechanism of action of this compound does not probably involve apoptosis. An attempt was made to study apoptosis but, unfortunately, this compound presents fluorescence, interfering with the assays that we have currently implemented in our laboratory (Annexin V/PI labelling by flow cytometry and TUNEL).
QSAR studies for anti-HCC and hepatotoxicity activities
The anti-HCC activity and hepatotoxicity of the methyl 3-amino-thieno[3,2-b]pyridine-2-carboxylates derivatives was studied and a SAR analysis was performed. Still, this analysis was purely based on chemical intuitions on the substituent effects of series of compounds.
To better understand the studied biological activities in a quantitative manner, and to provide insights on the mechanism of action, we set out to perform QSAR studies.
Compounds with no calculated GI 50 values, due to lack of biological activity up to the 125 µM DMSO solubility limit, were not used for this (were left out of this) analysis, as they would distort this quantitative analysis. In the end QSAR studies were performed with: ten compounds with anti-HCC activity (1b, 1d, 1j, 1s, 1t, 2f, 2g, 2j, 2l and 2m ) and 16 with hepatotoxic activity (1b, 1e, 1i, 1j, 1n, 1o, 1p, 1q, 1r, 1s, 1t, 2a, 2b, 2d, 2l and 2n) . Then, a total of 1664 molecular descriptors were calculated for each of the selected compound, using the E-Dragon software [21, 22] From the molecular properties and 1D categories, only the Hy (hydrophilic factor), the nHDon (the number of hydrogen Donors) and nArNH2 (number of amino groups linked to aryl group) descriptors provided good correlations with anti-HCC activity. This information is in agreement with the SAR analysis made before, and demonstrates that amino groups linked to aryl (nArNH2) is a key factor on anti-HCC activity. In fact, the amino group was the only substituent used with hydrogen bond donating capability, thus explaining the nHDon descriptor correlation and consequently the Hy descriptor. We can assume that probably other functional groups hydrogen bond donors, in the same positions as the amino groups, may yield similar or better anti-HCC activities. Table 4 Symbols for the descriptors used and their definition.
Category Symbols Descriptor definition
Hy hydrophilic factor Molecular Properties AlogP
Ghose-Crippen octanol-water partition coefficients (logP) regarding molecular size, shape, symmetry, and atom distribution with respect to some invariant reference frame. Thus they usually perform better when the spatial configuration and the stereo-chemistry of the compounds are determinant factors to the biological activity studied, in this case the anti-HCC [23, 24] . Therefore, the main mechanism of action of the methyl 3-aminothieno[3,2-b]pyridine-2-carboxylates derivatives is probably as modulators of protein targets involved in signaling pathways that have been associated with HCC [25] .
As more methyl 3-amino-thieno[3,2-b]pyridine-2-carboxylates derivatives will be synthesized, we expect to translate this information into predictive QSAR models, probably using the WHIM descriptors.
When we correlate descriptors with hepatotoxicity, we observe that only 1D and 3D The 3D descriptors that better correlate with hepatotoxicity belong to the GETAWAY (GEometry, Topology, and Atom-Weights AssemblY) category. These descriptors are based on matching 3D-molecular geometry with chemical information, and are based on well-known accepted algorithms and formula, possessing a track record of good predictive power in biological property modeling [23, 26] . The fact that hepatotoxicity correlates with 3D descriptors from a different category, when compared to the anti-HCC activity, is also an indication that the mechanism of action in both biological activities is probably different.
Although the PLP1 cell culture used is not a "pure" hepatocytes culture, biotransformation of the methyl 3-aminothieno[3,2-b]pyridine-2-carboxylates derivatives is also probably a factor in the observed hepatotoxicity, as the metabolites produced are probably the cause of toxicity. This information is impossible to derive from the 3D descriptors and the hepatotoxicity mechanism will become more apparent as more studies, specially in vivo assays, are performed.
Conclusions
In this study, a total of thirty-two methyl 3-amino-thieno [ HepG2 cell cycle analysis of compound 2f indicates that the mechanism of action of this compound is related with G2/M cell cycle arrest.
QSAR studies were also performed, and revealed that the 3D-WHIM descriptors were the ones that correlated best with anti-HCC activity, while the 3D-GETWAY descriptors correlated best with hepatotoxicity. All together, these findings indicate that the studied compounds promote anti-HCC and hepatotoxicity through different mechanisms, probably also as modulators of protein kinase targets such as growth factor receptors involved in different signaling pathways. These studies have also confirmed the importance of the presence of the amino groups, and of hydrogen bond donors in general. In conclusion, several compounds present potent in vitro anti-HCC activity using HepG2 cells without hepatotoxicity. Furthermore, they might be used as scaffolds for synthesis of even more potent compounds.
Experimental
Tested compounds
Thirty 
Reagents
Dulbecco's modified Eagle's medium, hank's balanced salt solution (HBSS), fetal bovine serum (FBS), L-glutamine, trypsin-EDTA, penincillin/streptomycin solution (100 U/mL and 100 mg/mL, respectively), all purchased from Gibco Invitrogen LifeTechnologies (California, USA). Sulforhodamine B, trypan blue, acetic acid, dimethyl sulfoxide (DMSO), ellipticine, ethylene diamine tetraacetic acid (EDTA), Trichloroacetic acid (TCA) and Tris were purchased from SigmaChemical Co. (Saint Louis, USA).
Cell Lines
In this work, two cell lines were used, the human hepatocellular liver carcinoma cell line HepG2 and a porcine liver primary cell culture (PLP1). The PLP1 cell culture was prepared from a freshly harvested porcine liver obtained from a local slaughter house. Briefly, the liver tissues were rinsed in hank's balanced salt solution containing 100 U/mL penicillin, 100 ug/mL streptomycin (Gibco Invitrogen Life Technologies) and divided into 1×1 mm 3 explants. Some of these explants were placed in 25 cm 2 tissue flasks in DMEM medium supplemented with 10% fetal bovine serum, 2 mM nonessential amino acids and 100 U/mL penicillin, 100 mg/mL streptomycin. Both cell lines were incubated at 37°C with a humidified atmosphere containing 5% CO 2 . The medium was changed every two days.
Cultivation of the cells was continued with direct monitoring every two to three days using a phase contrast microscope.
Before confluence was reached, both HepG2 and PLP1 cells were subcultured and plated in 96-well plates at a density of 2.5×10 4 cells/well, and cultivated in DMEM medium with 10% FBS, 100 U/mL penicillin and 100 mg/mL streptomycin.
Cell Growth Inhibition Assay using HepG2 and PLP1 cells.
The tested compounds in vitro effect on HepG2 and PLP1 cell growth was studied, using the sulforhodamine B (SRB) colorimetric assay [27] ºC. Plates were then washed with deionized water and dried; SRB solution (0.1% wt/vol in 1% acetic acid, 50 µL) was then added to each plate well and incubated for 30 min at room temperature. Unbound SRB was removed by washing with 1% acetic acid. Plates were airdried and bound stain was solubilized with 100 µL of a 100 mM Tris base solution. Optical densities were read on an automated spectrophotometer plate reader at a single wavelength of 540 nm (Biotek Elx800). Dose-response curves were obtained for each tested compound and cell line, and the GI 50 value, corresponding to the concentration of the compounds that inhibited 50 % of the net cell growth, was calculated as described elsewhere [28] . The GI 50 values are expressed as mean ± SEM of three independent experiments. RNase A and 5 µg/mL propidium iodide. The cellular DNA content was analysed by flow cytometry using an Epics XL-MCL Coulter Flow cytometer (Brea, CA, USA) plotting at least 5 000 events per sample, as previously described [17, 29] . The % of cells in G0/G1, S and G2/M phases of the cell cycle and the % of cells in the sub-G1 peak were determined using the FlowJo 7.2 software (Tree Star, Inc., Ashland, OR, USA) after cell debris and aggregates exclusion.
Analysis of cell cycle profile
3D structure preparation and molecular descriptors calculation
The 2D chemical structures of the tested compounds were drawn using the Symyx/Draw software [30] . Then, 2D to 3D structure conversion and geometry optimization calculations were performed for each compound, using the AMMP force field sp4 [31] , developed on the basis of the UFF potential set [32] and available via the VegaZZ software [33] . Finally the 3D structure of each compound was recorded in mol2 file format also using the VegaZZ software. The E-Dragon computer software was then employed to calculate the molecular descriptors totaling 1664 descriptors belonging to different categories: molecular properties, OD, 1D, 2D and 3D [20, 23] 
